Can I Take Zinc with Leqvio (Inclisiran)?

How Inclisiran Works, and Why That Matters for Supplement Interactions

Inclisiran's mechanism is unusually narrow compared to most small-molecule drugs. Understanding it explains why so many conventional drug interactions simply do not apply.

Inclisiran is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, the GalNAc ligand binds asialoglycoprotein receptors on hepatocytes with high selectivity, delivering the siRNA almost exclusively to liver cells. Inside the hepatocyte, inclisiran silences the PCSK9 gene post-transcriptionally, which reduces PCSK9 protein synthesis and allows LDL receptors to recycle normally, lowering circulating LDL-cholesterol by roughly 50% [1, 2].

No Cytochrome P450 Involvement

Most diet-drug and supplement-drug interactions occur because a compound inhibits or induces CYP3A4, CYP2C9, or one of the other cytochrome P450 enzymes responsible for metabolising medications. Inclisiran bypasses this system entirely. The FDA prescribing information for Leqvio states that inclisiran "is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or drug transporters" [3]. That single fact rules out a large category of potential interactions.

Renal Excretion and Plasma Protein Binding

Roughly 16% of an inclisiran dose is excreted unchanged in urine. The drug binds moderately (approximately 87%) to plasma proteins. Neither of these properties is affected by zinc at physiological or even high-supplemental concentrations. Zinc is a trace mineral handled through the GI tract, portal circulation, and metallothionein-mediated sequestration; it does not compete for the renal transporters or albumin binding sites relevant to inclisiran.

What Zinc Does in the Body

Zinc is an essential trace element present in more than 300 enzymatic reactions. Adults need 8 to 11 mg/day from food and supplements combined. The NIH Office of Dietary Supplements sets the tolerable upper intake level (UL) at 40 mg/day for adults [4].

Zinc and Cholesterol Metabolism

Here is where the question becomes clinically interesting. Zinc plays a role in lipid metabolism, although the direction of that effect depends on dose and context. A meta-analysis of 33 randomised controlled trials (N=1,570) published in Nutrients (2020) found that zinc supplementation produced a statistically significant reduction in total cholesterol (weighted mean difference: -9.41 mg/dL, P<0.001) and LDL-cholesterol (-6.87 mg/dL, P<0.001) [5]. Those reductions are modest compared to inclisiran's ~50% LDL reduction, and they work through entirely different pathways.

The Copper-Zinc Ratio

High-dose zinc (above 50 mg/day sustained for weeks) inhibits intestinal copper absorption by upregulating the copper-binding protein metallothionein in enterocytes. Copper deficiency, if it develops, can produce anaemia and, in rare cases, neurological symptoms. More relevant to cardiovascular patients: copper is a cofactor for ceruloplasmin and for the enzyme superoxide dismutase (SOD1), both of which matter for vascular oxidative stress [6].

This indirect pathway is the only biologically plausible concern when combining high-dose zinc with any cardiovascular medication, including inclisiran. At standard supplement doses (8 to 25 mg/day), the risk is negligible.

Direct Interaction Evidence: Zinc and Inclisiran

No published randomised trial, case report, or pharmacokinetic study has examined zinc co-administration with inclisiran specifically. The ORION clinical trial programme, which enrolled more than 3,600 patients across ORION-9, ORION-10, and ORION-11, did not screen participants for zinc intake or report zinc-related adverse events, meaning zinc use was neither restricted nor flagged [1, 2, 7].

Why a Direct PK Interaction Is Unlikely

The absorption of inclisiran (subcutaneous route, peak plasma concentration at approximately 4 hours) is independent of GI transit. Zinc supplements taken orally do not enter the systemic circulation at concentrations capable of displacing inclisiran from protein-binding sites or altering hepatic uptake via the GalNAc receptor pathway. The two substances simply do not share metabolic real estate.

PCSK9 and Zinc: Any Signal?

A small but growing body of basic-science research explores whether zinc status affects PCSK9 expression. One in vitro study published in Molecular Nutrition and Food Research (2019) found that zinc deprivation in HepG2 cells modestly upregulated PCSK9 mRNA, suggesting that adequate zinc may slightly suppress PCSK9 at the cellular level [8]. If this effect translates to humans, zinc repletion could theoretically complement inclisiran's PCSK9-silencing action rather than oppose it. The clinical magnitude of any such effect is unknown and should not change prescribing decisions, but it argues against any antagonism between the two.

Clinical Takeaway from the Evidence Gap

An absence of identified interaction is not the same as a confirmed interaction with a zero effect size. Standard scientific caution applies. The current evidence supports co-administration at standard supplemental doses, and monitoring is straightforward if higher doses are used.

Inclisiran's Clinical Evidence Base

Before placing any supplement concern in context, it helps to understand how robustly inclisiran's efficacy and safety are established.

ORION-10 and ORION-11 Trial Results

ORION-10 enrolled 1,561 patients with ASCVD on maximally tolerated statin therapy. At 510 days, inclisiran 284 mg every 6 months reduced LDL-cholesterol by 52.3% from baseline compared with a 0.5% reduction in the placebo group (P<0.001) [1]. ORION-11 (N=1,617, patients with ASCVD or ASCVD risk equivalents) showed a 49.9% LDL-C reduction versus a 1.8% reduction with placebo at the same timepoint [2].

The FDA approved inclisiran in December 2021. The European Medicines Agency had approved it a year earlier in December 2020 [3].

Safety Profile Relevant to Supplement Users

Across pooled ORION data, the most common adverse events were injection-site reactions (8.2% inclisiran vs. 1.8% placebo). No hepatotoxicity signal emerged despite the hepatocyte-targeted delivery. No clinically meaningful changes in liver enzymes, renal function, or electrolytes, including zinc-related trace mineral panels, were reported in the pooled safety analysis [1, 2].

The prescribing information does not list any supplement interactions under the drug-interactions section [3]. This is consistent with inclisiran's pharmacology: a drug that never touches CYP450, bypasses the gut entirely, and acts intracellularly inside a single cell type leaves very little surface area for conventional drug-nutrient interactions.

Should You Separate Zinc and Leqvio Doses?

Dose separation is commonly recommended when a mineral supplement can chelate or bind a drug in the GI tract, the way calcium binds tetracycline antibiotics or iron binds levothyroxine. Inclisiran is given as a subcutaneous injection, not orally. There is no GI co-absorption step. Dose separation is therefore not required or recommended [3].

What About IV or Infusion Formulations?

Inclisiran is administered exclusively as a subcutaneous injection in a clinic or physician's office. No oral or intravenous formulation exists. This rules out the IV compatibility questions that arise with some injectable mineral preparations. You can take your zinc supplement at any time of day relative to your Leqvio injection appointment.

Zinc Dosing Guidance for People on Leqvio

The following guidance is consistent with NIH ODS recommendations and standard cardiovascular nutrition practice.

Standard Supplemental Doses (8 to 25 mg/day)

Doses in this range are safe for the vast majority of adults. They will not perturb copper metabolism, will not affect inclisiran's mechanism, and require no additional monitoring beyond your routine lipid panel at 3 months post-injection [4].

Higher Doses (25 to 40 mg/day)

Some patients take higher zinc doses for immune support or wound healing. Staying at or below the 40 mg/day UL is advisable for anyone on a long-term cardiovascular medication programme, not because of inclisiran specifically, but because sustained high-zinc intake can gradually deplete copper. A serum copper or ceruloplasmin check is reasonable if you plan to remain above 25 mg/day for more than 8 weeks.

Therapeutic Doses Above 40 mg/day

Zinc above 40 mg/day is occasionally prescribed for conditions such as Wilson's disease or acrodermatitis enteropathica. At these doses, co-administration of a copper supplement (1 to 2 mg/day copper) is standard practice to prevent deficiency [4]. If you are in this category, your prescribing clinician should be coordinating both the zinc and any cardiovascular medications including inclisiran.

Other Supplements to Watch More Carefully with Leqvio

Zinc carries low interaction risk. A few other common supplements deserve more attention in the inclisiran-treated patient.

Red Yeast Rice

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. Patients taking inclisiran are typically already on a statin, and adding red yeast rice creates an unquantified additive statin dose, raising myopathy risk. The FDA has taken action against red yeast rice products with measurable monacolin K content [9].

High-Dose Niacin (Above 1 g/day)

The AIM-HIGH trial (N=3,414) found no incremental cardiovascular benefit from extended-release niacin added to statin therapy and noted increased stroke risk at 3 years [10]. High-dose niacin also causes significant flushing and glucose dysregulation. Its LDL-lowering effect is minimal compared to inclisiran, and its risk-benefit ratio in ASCVD patients is unfavourable.

Omega-3 Fatty Acids (Standard Doses)

Fish oil at 1 to 4 g/day of EPA/DHA does not interact with inclisiran's siRNA mechanism. The REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid 4 g/day (prescription Vascepa) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides [11]. Standard OTC fish oil is not equivalent to prescription EPA, but neither is it harmful with inclisiran.

Monitoring Checklist for Patients Taking Zinc and Leqvio Together

A practical framework for clinicians and patients:

| Timepoint | Test | Reason | |---|---|---| | Baseline (before first Leqvio injection) | Fasting lipid panel, LFTs, CMP | Establish reference values | | 3 months post-first injection | Fasting LDL-C | Confirm ~50% response per ORION data | | Every 6 months with each injection | Fasting lipid panel | Ongoing efficacy monitoring | | If zinc dose exceeds 25 mg/day for 8+ weeks | Serum copper, ceruloplasmin, CBC | Screen for copper depletion | | If zinc dose exceeds 40 mg/day | Add copper supplement 1 to 2 mg/day | Prevent copper-deficiency anaemia |

What HealthRX Clinicians Recommend

The guidance from the HealthRX medical team for patients asking about zinc while taking Leqvio is consistent and direct: zinc at standard supplement doses (up to 25 mg/day) does not interfere with inclisiran's mechanism, absorption, metabolism, or efficacy. No dose separation is needed. No additional blood work is needed beyond the standard 3-month lipid check already required to confirm treatment response.

If you take zinc above 40 mg/day for a specific medical reason, tell the provider managing your Leqvio therapy so copper status can be monitored. That precaution is about long-term zinc safety in general, not about any specific interaction with inclisiran.

Inclisiran's every-six-month dosing schedule, administered in a clinical setting rather than self-administered daily, actually reduces the practical risk of supplement interactions compared to daily oral medications. You are not swallowing a tablet alongside zinc each morning; the injection happens twice a year in a controlled environment.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway for PCSK9 inhibitors notes that "non-statin therapies including PCSK9 inhibitors should be considered in all patients who cannot achieve LDL-C goals on maximally tolerated statin therapy" and makes no restrictions on concurrent supplement use [12]. That document covers monoclonal antibody PCSK9 inhibitors and inclisiran collectively under the PCSK9-inhibitor class.

Inclisiran Adherence: Why the Dosing Schedule Matters More Than Supplements

Adherence to the every-6-month injection schedule is the single largest determinant of whether inclisiran works. A modelling study using ORION-10 data estimated that missing even one injection could allow LDL-C to drift back toward 70 to 80% of pre-treatment baseline within 6 months, given the 9-month half-life of PCSK9 gene silencing [1].

By comparison, the effect of any supplement on LDL-C, whether zinc (which may reduce LDL by ~6 to 7 mg/dL at best) or plant sterols (which reduce LDL by ~8 to 10% in controlled studies) is an order of magnitude smaller than what is lost by a missed Leqvio injection. Keeping your clinic appointment matters far more than optimising your supplement stack.